Business Context and Reporting Period
This Form 8-K, dated April 23, 2020, reports on BioRestorative Therapies, Inc., a Delaware corporation. The Company is currently operating as a "debtor-in-possession" following a voluntary Chapter 11 bankruptcy filing on March 20, 2020, in the United States Bankruptcy Court for the Eastern District of New York (Case No. 8-20-71757).
Key Financial Metrics and Liquidity
The filing focuses on the approval of Debtor-in-Possession (DIP) financing rather than standard operating metrics. The filing text does not provide clear values for revenue, profit, cash flow, or operating margins.
- DIP Financing Facility: A senior secured superpriority credit facility of up to $713,000.
- Interim Funding Approved: Approximately $354,000.
- Funds Received: Approximately $244,000 received on April 24, 2020.
- Interest Rate: 8% per annum payable in arrears; increases to current rate plus 2% upon an event of default.
- Collateral: First priority lien on all tangible and intangible property and assets of the Company.
Material Changes
The primary material change is the execution of a Secured Term Note and Security Agreement with Auctus Fund, LLC on April 23, 2020. This agreement was approved by the Bankruptcy Court via an Interim DIP Order to provide necessary liquidity for the Company to continue operations during the Chapter 11 proceedings.
Outlook, Risks, and Contingencies
Use of Proceeds: Funds are designated for working capital, general purposes, United States Trustee fees, professional fees, administrative expenses, and interest/costs related to the DIP Financing.
Maturity Date: The earliest of July 6, 2020; ten days following the confirmation of a Chapter 11 plan; ten days following the approval of a sale of the Company or its assets; or the occurrence of an event of default.
Risks and Contingencies:
- Uncertainty regarding the approval of future motions by the Bankruptcy Court.
- Risks associated with the length of the Chapter 11 case and the ability to implement strategic alternatives.
- Potential acceleration of debt obligations.
- Volatility of common stock trading on the OTC Pink Market.
Investor Verification Checklist
- Verify the status of the "Final DIP Order" required to approve the full $713,000 facility.
- Confirm the Company's ability to meet the July 6, 2020 maturity date or secure a plan confirmation/asset sale prior to that date.
- Review the full text of the Secured Term Note (Exhibit 10.1) and Security Agreement (Exhibit 10.2) for specific default triggers and carve-outs.
- Monitor subsequent filings for updates on the Chapter 11 case progress and any additional financing needs.